Revolutionizing Cancer Therapy with 3-Dimentional (3D) “Synthetic Peptide” Drugs
Pepto*ID is developing universally applicable 3D synthetic peptide therapeutics for difficult to treat cancers – overcoming key limitations of conventional drug types
Who We Are
By leveraging next-generation chemistry and biology, we engineer structurally defined molecules with enhanced stability, cell/tissue permeability, target selectivity, and drug-like properties.
Our platform is designed to enable new therapeutic approaches across challenging cancer targets, including tumors characterized by heterogeneity and drug resistance.
Our integrated discovery and development approach combines proprietary discovery platforms, lead optimization, and scalable synthesis to provide a streamlined path from hit discovery to candidate development, helping promising therapeutic concepts to advance efficiently through the development process.
Why Pepto*ID Is Unique
Pepto*ID combines flexible molecular design with our unique On-Bead Two-Color (OBTC) high-
throughput cell screening technology to identify highly selective drug candidates across diverse
therapeutic targets. Our integrated discovery and development platform can be tailored to the
structural and chemical requirements of difficult-to-target therapeutic biomarkers, rather than
being confined to a single molecular format or target class.
This flexibility also enables us to pursue new therapeutic strategies for both intrinsic and treatment-
emergent drug resistance, including approaches directed toward shared cancer-associated
biomarkers. Importantly, built-in drug-like properties such as stability, cell permeability, and
bioavailability can be incorporated from the outset, reducing the need for expensive post-discovery
optimization and helping streamline candidate development.
Our Platform Technology
Versatile 3D Synthetic Peptide Architecture Design
Flexible molecular design enables diverse 3D architectures and chemical functionalities tailored
to different therapeutic targets.
HTS Drug-Lead Identification
The unique On-Bead Two-Color (OBTC) High-Throughput Screening (HTS) technology that can quickly identify the most selective “hit” compounds for your favorite drug target over the rest of the cellular biomarkers – minimizing future failures due to off target effects.
Overcoming Drug Resistance
Mutation agnostic mechanisms of actions to avoid developing drug resistance.
Stability & Bioavailability
Already optimized “hit” structures directly identified with enhanced resistance to degradation and improved pharmacokinetics/pharmacodynamic (PK/PD) properties.
Scalable Synthesis
Robust manufacturing approaches enabling scalable production of clinical-grade Synthetic Peptide drug candidates.
OUR PIPELINE
PID-01
Mutation agnostic lead candidate directly targeting KRAS as a true “Pan-KRAS inhibitor” for advanced solid tumors (e.g. NSCLC, PDAC etc.); demonstrating potent anticancer activity in preclinical models.
PID-02
Next-generation therapeutic optimized for cell surface plectin for metastatic tumors with
the potential for combination therapy.
PID-03
Unique therapeutic targeting cell surface lipid-phosphatidylserine (PS) as a solution for
protein heterogeneity and therefore universally targeted cancer treatment development.
Discovery & Research Programs
Ongoing discovery programs focusing on novel cancer targets and resistant phenotypes.
Future Innovation
Expansion into universally applicable immuno-oncology targeted platforms leveraging
OUR TEAM
TANU CHATTERJI, PhD
Director, Startup Development and UH Technology Bridge Incubator
ALOE BLACC
Grammy-nominated, multi-platinum, singer/songwriter, known for major hits such as “I Need A Dollar”, “The Man”, and “Wake Me Up”, pledged early in his career to use his music for positive social transformation.
GOMIKA UDUGAMASOORIYA, PhD
Professor Udugamasooriya, affiliated with the University of Houston and the MD
Anderson Cancer Center, holds a number of patents and is a Senior Member of the
National Academy of Inventors (NAI) in United States